SG11201504200TA - Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases - Google Patents
Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseasesInfo
- Publication number
- SG11201504200TA SG11201504200TA SG11201504200TA SG11201504200TA SG11201504200TA SG 11201504200T A SG11201504200T A SG 11201504200TA SG 11201504200T A SG11201504200T A SG 11201504200TA SG 11201504200T A SG11201504200T A SG 11201504200TA SG 11201504200T A SG11201504200T A SG 11201504200TA
- Authority
- SG
- Singapore
- Prior art keywords
- gamma
- ror
- retinoid
- modulators
- autoimmune
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012001636 | 2012-12-06 | ||
| CN2013000182 | 2013-02-25 | ||
| CN2013000803 | 2013-07-01 | ||
| PCT/EP2013/075594 WO2014086894A1 (en) | 2012-12-06 | 2013-12-05 | Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201504200TA true SG11201504200TA (en) | 2015-06-29 |
Family
ID=49709687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201504200TA SG11201504200TA (en) | 2012-12-06 | 2013-12-05 | Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US10005731B2 (hu) |
| EP (2) | EP3219711A1 (hu) |
| JP (1) | JP6279605B2 (hu) |
| KR (1) | KR20150092244A (hu) |
| CN (1) | CN105121430B (hu) |
| AR (1) | AR093818A1 (hu) |
| AU (1) | AU2013354109B2 (hu) |
| BR (1) | BR112015013137B1 (hu) |
| CA (1) | CA2894016C (hu) |
| CL (1) | CL2015001557A1 (hu) |
| CR (1) | CR20150302A (hu) |
| CY (1) | CY1118932T1 (hu) |
| DK (1) | DK2928885T3 (hu) |
| EA (1) | EA026437B1 (hu) |
| ES (1) | ES2626390T3 (hu) |
| HK (1) | HK1214814A1 (hu) |
| HR (1) | HRP20170638T1 (hu) |
| HU (1) | HUE033212T2 (hu) |
| IL (1) | IL239082A0 (hu) |
| LT (1) | LT2928885T (hu) |
| ME (1) | ME02696B (hu) |
| MX (1) | MX2015007180A (hu) |
| PE (1) | PE20151144A1 (hu) |
| PH (1) | PH12015501244A1 (hu) |
| PL (1) | PL2928885T3 (hu) |
| PT (1) | PT2928885T (hu) |
| RS (1) | RS55875B1 (hu) |
| SG (1) | SG11201504200TA (hu) |
| SI (1) | SI2928885T1 (hu) |
| TW (1) | TW201427959A (hu) |
| UY (1) | UY35174A (hu) |
| WO (1) | WO2014086894A1 (hu) |
| ZA (1) | ZA201503666B (hu) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9745297B2 (en) | 2013-07-30 | 2017-08-29 | Boehringer Ingelheim International Gmbh | Compounds as modulators of RORC |
| LT3102576T (lt) | 2014-02-03 | 2019-08-12 | Vitae Pharmaceuticals, Llc | Ror-gama dihidropirolopiridino inhibitoriai |
| EP3148987B1 (en) * | 2014-05-28 | 2019-01-02 | GlaxoSmithKline Intellectual Property Development Limited | Piperazine derivatives as ror-gamma modulators |
| KR20170012389A (ko) * | 2014-05-28 | 2017-02-02 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 신규 화합물 |
| AU2015267910B2 (en) | 2014-05-28 | 2017-10-26 | Glaxosmithkline Intellectual Property Development Limited | Novel compounds |
| CN104292208A (zh) * | 2014-09-09 | 2015-01-21 | 上海师范大学 | 7-苯基-6,8-二氧杂螺[3.5]壬烷-2-羧酸及其制备方法 |
| MA40759A (fr) * | 2014-09-26 | 2017-08-01 | Pfizer | Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation |
| UA118989C2 (uk) | 2014-10-14 | 2019-04-10 | Вітае Фармасьютікалс, Інк. | Дигідропіролопіридинові інгібітори ror-гамма |
| US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
| TW201625588A (zh) * | 2014-11-05 | 2016-07-16 | 第一三共股份有限公司 | 環狀胺衍生物 |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| US10336748B2 (en) | 2015-01-30 | 2019-07-02 | Pfizer Inc. | Methyoxy-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof |
| US10301261B2 (en) | 2015-08-05 | 2019-05-28 | Vitae Pharmaceuticals, Llc | Substituted indoles as modulators of ROR-gamma |
| US11008340B2 (en) * | 2015-11-20 | 2021-05-18 | Vitae Pharmaceuticals, Llc | Modulators of ROR-gamma |
| TW202220968A (zh) | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| AU2017294969B2 (en) * | 2016-07-13 | 2021-03-25 | Leo Pharma A/S | Heteroaromatic modulators of the retinoid-related orphan receptor gamma |
| CN109134476B (zh) * | 2017-06-15 | 2021-03-19 | 复旦大学 | 桥环哌嗪类衍生物或其盐及其制备方法和用途 |
| JP6737967B1 (ja) * | 2017-07-18 | 2020-08-12 | ロンザ リミテッドＬｏｎｚａ Ｌｉｍｉｔｅｄ | ５−フルオロ−２−メチル−３−ニトロ安息香酸およびそのメチルエステルを製造する方法 |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| IL298639A (en) | 2017-07-24 | 2023-01-01 | Vitae Pharmaceuticals Llc | Inhibitors of gamma ror |
| CN108752185A (zh) * | 2018-07-17 | 2018-11-06 | 成都道合尔医药技术有限公司 | 一种1-氟-环戊甲酸的合成方法 |
| CN109438423A (zh) * | 2018-09-12 | 2019-03-08 | 通化师范学院 | 一种肺癌靶向化合物azd-3759的合成工艺的新方法 |
| CN110862319A (zh) * | 2019-12-04 | 2020-03-06 | 深圳振强生物技术有限公司 | 奥扎格雷杂质的制备方法 |
| WO2023232870A1 (en) | 2022-05-31 | 2023-12-07 | Immunic Ag | Rorg/rorgt modulators for the treatment of virus infections like covid-19 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7790726B2 (en) | 2005-08-16 | 2010-09-07 | Chemocentryx, Inc. | Monocyclic and bicyclic compounds and methods of use |
| US20070208000A1 (en) * | 2005-12-15 | 2007-09-06 | Morgan Bradley P | Certain chemical entities, compositions and methods |
| US7825120B2 (en) * | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
| WO2007078839A2 (en) * | 2005-12-19 | 2007-07-12 | Cytokinetics, Inc. | Compounds, compositions and methods |
| WO2012028100A1 (en) | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
| WO2012027965A1 (en) | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
| WO2012100732A1 (en) | 2011-01-24 | 2012-08-02 | Glaxo Group Limited | Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof |
| WO2012100734A1 (en) | 2011-01-24 | 2012-08-02 | Glaxo Group Limited | Compounds useful as retinoid-related orphan receptor gamma modulators |
| EP2511263A1 (en) * | 2011-04-14 | 2012-10-17 | Phenex Pharmaceuticals AG | Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases |
| WO2012145254A2 (en) | 2011-04-16 | 2012-10-26 | Board Of Regents, The University Of Texas System | Methods of using inhibitors of rorϒt to treat disease |
| WO2012147916A1 (ja) | 2011-04-28 | 2012-11-01 | 日本たばこ産業株式会社 | アミド化合物およびその医薬用途 |
| US9586928B2 (en) * | 2011-05-16 | 2017-03-07 | The Scripps Research Institute | Modulators of the nuclear hormone receptor ROR |
| MX2014002810A (es) | 2011-09-09 | 2014-09-08 | Univ New York | Compuestos amido como moduladores del receptor nuclear huérfanoyt y usos de los mismos. |
| GB201116641D0 (en) | 2011-09-27 | 2011-11-09 | Glaxo Group Ltd | Novel compounds |
| GB201207406D0 (en) | 2012-04-27 | 2012-06-13 | Glaxo Group Ltd | Novel compounds |
| JP6182594B2 (ja) | 2012-04-27 | 2017-08-16 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | 新規化合物 |
| WO2013171729A2 (en) | 2013-01-08 | 2013-11-21 | Glenmark Pharmaceuticals S.A. | Aryl and heteroaryl amide compounds as rorgamat modulator |
| EP3060553A4 (en) | 2013-10-25 | 2017-03-29 | Glaxosmithkline LLC | Novel compounds |
| WO2015061686A2 (en) | 2013-10-25 | 2015-04-30 | St. Jude Children's Research Hospital, Inc. | Retinoid x receptor-gamma agonists and retinoid x receptor-alpha antagonists for treatment of cancer |
| KR20170012389A (ko) | 2014-05-28 | 2017-02-02 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 신규 화합물 |
| EP3148987B1 (en) | 2014-05-28 | 2019-01-02 | GlaxoSmithKline Intellectual Property Development Limited | Piperazine derivatives as ror-gamma modulators |
| AU2015267910B2 (en) | 2014-05-28 | 2017-10-26 | Glaxosmithkline Intellectual Property Development Limited | Novel compounds |
-
2013
- 2013-12-05 HU HUE13799318A patent/HUE033212T2/hu unknown
- 2013-12-05 PL PL13799318T patent/PL2928885T3/pl unknown
- 2013-12-05 JP JP2015546002A patent/JP6279605B2/ja active Active
- 2013-12-05 UY UY0001035174A patent/UY35174A/es unknown
- 2013-12-05 EA EA201591059A patent/EA026437B1/ru not_active IP Right Cessation
- 2013-12-05 CN CN201380070619.3A patent/CN105121430B/zh active Active
- 2013-12-05 CA CA2894016A patent/CA2894016C/en active Active
- 2013-12-05 KR KR1020157017633A patent/KR20150092244A/ko not_active Application Discontinuation
- 2013-12-05 US US14/649,585 patent/US10005731B2/en active Active
- 2013-12-05 EP EP17157475.9A patent/EP3219711A1/en not_active Withdrawn
- 2013-12-05 ES ES13799318.4T patent/ES2626390T3/es active Active
- 2013-12-05 ME MEP-2017-117A patent/ME02696B/me unknown
- 2013-12-05 AR ARP130104518A patent/AR093818A1/es unknown
- 2013-12-05 SI SI201330650A patent/SI2928885T1/sl unknown
- 2013-12-05 DK DK13799318.4T patent/DK2928885T3/en active
- 2013-12-05 TW TW102144579A patent/TW201427959A/zh unknown
- 2013-12-05 EP EP13799318.4A patent/EP2928885B1/en active Active
- 2013-12-05 PE PE2015000712A patent/PE20151144A1/es not_active Application Discontinuation
- 2013-12-05 PT PT137993184T patent/PT2928885T/pt unknown
- 2013-12-05 RS RS20170372A patent/RS55875B1/sr unknown
- 2013-12-05 MX MX2015007180A patent/MX2015007180A/es unknown
- 2013-12-05 BR BR112015013137-9A patent/BR112015013137B1/pt active IP Right Grant
- 2013-12-05 SG SG11201504200TA patent/SG11201504200TA/en unknown
- 2013-12-05 LT LTEP13799318.4T patent/LT2928885T/lt unknown
- 2013-12-05 AU AU2013354109A patent/AU2013354109B2/en not_active Ceased
- 2013-12-05 WO PCT/EP2013/075594 patent/WO2014086894A1/en active Application Filing
-
2015
- 2015-05-22 ZA ZA2015/03666A patent/ZA201503666B/en unknown
- 2015-05-28 IL IL239082A patent/IL239082A0/en unknown
- 2015-06-02 PH PH12015501244A patent/PH12015501244A1/en unknown
- 2015-06-05 CL CL2015001557A patent/CL2015001557A1/es unknown
- 2015-06-08 CR CR20150302A patent/CR20150302A/es unknown
-
2016
- 2016-03-09 HK HK16102705.4A patent/HK1214814A1/zh not_active IP Right Cessation
-
2017
- 2017-04-24 HR HRP20170638TT patent/HRP20170638T1/hr unknown
- 2017-06-02 CY CY20171100587T patent/CY1118932T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL239082A0 (en) | Modulators of orphan gamma receptors attributed to retinoid (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases | |
| IL263020A (en) | New modulators and methods of use | |
| HK1216176A1 (zh) | 用於治療增殖性和自身免疫疾病的非對稱吡咯並苯並二氮雜卓二聚物 | |
| HRP20181398T1 (hr) | Specifična antitijela za amiloid polipeptida humanih otočića (hiapp) i njegova upotreba | |
| HK1210430A1 (en) | Agents that modulate immune cell activation and methods of use thereof | |
| PT2815769T (pt) | Fam19a5 para utilização no diagnóstico e tratamento de lesões do snc | |
| EP2830548A4 (en) | ORAL DEVICE COMPRISING A BOTTLE SIMULATOR AND METHOD FOR USE THEREOF | |
| IL227440A0 (en) | Spherical support device and methods of use | |
| IL236738B (en) | Human antibodies to gfra3 and methods of using them | |
| HK1197187A1 (en) | Anti-lrp5 antibodies and methods of use lrp5 | |
| EP2694530A4 (en) | NOVEL PEPTIDES THAT BIND TYPES OF CLASS II MAJOR HISTOCOMPATIBILITY COMPLEX AND THEIR USE FOR DIAGNOSIS AND TREATMENT | |
| EP2799539A4 (en) | HUMAN ARGINASE AND PEGYLATED HUMAN ARGINASE WITH FIXED POINT, AND USE THEREOF | |
| EP2970223A4 (en) | Novel Modulators of 5-Hydroxypropylamine Receptor 7 Activity and Methods of Use | |
| GB201214736D0 (en) | Inflammation imaging and therapy | |
| EP2903742A4 (en) | APPARATUS FOR REDUCING MATERIALS AND METHODS OF USE | |
| HK1206249A1 (en) | Human autotaxin antibodies and methods of use (autotaxin) | |
| EP2721003A4 (en) | NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER | |
| HK1202853A1 (en) | Thixotropic agents and methods of use | |
| EP2895474A4 (en) | LEGIBLE MODULATORS AND METHOD OF USE THEREFOR | |
| IL237719A0 (en) | Antibodies specific to (hiapp) human islet amylid polypeptide and their uses | |
| AU2012900762A0 (en) | Back Support and Rehabilitation Device |